References

clinmed

Клиническая медицина

Clinical Medicine (Russian Journal)

0023-21492412-1339

ООО «Медицинское информационное агентство»

10.30629/0023-2149-2022-100-7-8-346-356

clinmed-423

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Инфекция Clos tri dium diffi cile и ее влияние на течение воспалительных заболеваний кишечника

Clostridium diffi cile infection and its eff ect on the course of infl ammatory bowel diseases

Пургина

Д. С.

Purgina

D. S.

Пургина Даниэла Сергеевна (Purgina Daniela S.) — врач-гастроэнтеролог, диетолог

197183, Санкт-Петербург

Purgina Daniela S.

197183, St. Petersburg

Лялина

Л. В.

Lyalina

L. V.

Лялина Людмила Владимировна (Lyalina Lyudmila V.) — д-р мед.наук, профессор, заведующая лабораторией эпидемиологии инфекционных и неинфекционных заболеваний

197101, Санкт-Петербург; 191015, Санкт-Петербург

Lyalina Lyudmila V

197101, St. Petersburg; 191015, Saint Petersburg

Рассохин

В. В.

Rassokhin

V. V.

Рассохин Вадим Владимирович (Rassokhin Vadim V.) — д-р мед. наук, профессор кафедры социально значимых инфекций ; ведущий научный сотрудник; заведующий лабораторией хронических вирусных инфекций отдела экологической физиологии

197101, Санкт-Петербург; 197022, Санкт-Петербург

Rassokhin Vadim V.

197101, St. Petersburg; 197022, Saint Petersburg

«Лахта Клиника»Россия"Lahta Clinic"Russian Federation

ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияSt. Petersburg Scientifi c Research Institute of Epidemiology and Microbiology named after Pasteur; North-Western State Medical University named after I.I. Mechnikov of the Ministry of Healthcare of RussiaRussian Federation

ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава РоссииРоссияSt. Petersburg Scientifi c Research Institute of Epidemiology and Microbiology named after Pasteur; Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of RussiaRussian Federation

2022

30102022

1007-8346356

2022

Пургина Д.С., Лялина Л.В., Рассохин В.В.

Purgina D.S., Lyalina L.V., Rassokhin V.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.clinmedjournal.com/jour/article/view/423

Воспалительные заболевания кишечника (ВЗК) — распространенные аутоиммунные заболевания с желудочно-кишечными и внекишечными проявлениями и осложнениями. Наиболее частым инфекционным осложнением, связанным с ВЗК, является инфекция Clostridium diffi cile (C. diffi cile). Активное ВЗК предрасполагает к развитию инфекции C. diffi cile из-за изменений в микробиоме кишечника. C. diffi cile представляет собой токсин-продуцирующую бактерию, которая приводит к ухудшению течения ВЗК, увеличивая риск неэффективности лечения основного заболевания, госпитализации и хирургического вмешательства.

Infl ammatory bowel diseases (IBD) are common autoimmune diseases with gastrointestinal and extra-intestinal manifestations and complications. The most common infectious complication associated with IBD is infection with Clostridium diffi cile (C. diffi cile). Active IBD predisposes to C. diffi cile infection due to changes in the intestinal microbiome. C. diffi cile is a toxinproducing bacterium that leads to a worsening of the course of the main IBD, increasing the risk of ineff ective treatment of IBD, increased risk of hospitalization and surgery.

воспалительные заболевания кишечникаязвенный колитболезнь КронаClostridium diffi cile

Infl ammatory bowel diseasesulcerative colitisCrohn’s diseaseClostridium diffi cile

References1

Sethi A.K., Al-Nassir W.N., Nerandzic M.M., Bobulsky G.S., Donskey C.J. Persistence of skin contamination and environmental shedding of Clostridium diffi cile during and after treatment of C. diffi cile infection. Infect. Control Hosp. Epidemiol. 2010;31(1):21– 7. DOI: 10.1086/649016

Knight D.R., Riley T.V. Genomic Delineation of Zoonotic Origins of Clostridium diffi cile. Front Public Health. 2019;7:164. DOI: 10.3389/fpubh.2019.00164

Czepiel J., Dróżdż M., Pituch H., Kuijper EJ., Perucki W., Mielimonka A., Goldman S., Wultańska D., Garlicki A., Biesiada G. Clostridium diffi cile infection: review. Eur. J. Clin. Microbiol. Infect. Dis. 2019;38(7):1211–1221. DOI: 10.1007/s10096-019-03539-6

Lim S.C., Knight D.R., Riley T.V. Clostridium diffi cile and One Health. Clin. Microbiol. Infect. 2020;26(7):857–863. DOI: 10.1016/j.cmi.2019.10.023

Regnault H., Bourrier A., Lalande V., Nion-Larmurier I., Sokol H., Seksik P., Barbut F., Cosnes J., Beaugerie L. Prevalence and risk factors of Clostridium diffi cile infection in patients hospitalized for fl are of infl ammatory bowel disease: a retrospective assessment. Dig. Liver Dis. 2014;46(12):1086–92. DOI: 10.1016/j.dld.2014.09.003

Leffl er D.A., Lamont J.T. Clostridium diffi cile infection. N. Engl. J. Med. 2015;372(16):1539–48. DOI: 10.1056/NEJMra1403772

Hensgens M.P., Goorhuis A., Dekkers O.M., Kuijper E.J. Time interval of increased risk for Clostridium diffi cile infection after exposure to antibiotics. J. Antimicrob. Chemother. 2012;67(3):742–8. DOI: 10.1093/jac/dkr508

Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Orenstein R., St Sauver J.L., Harmsen W.S., Zinsmeister A.R. The epidemiology of community-acquired Clostridium diffi cile infection: a populationbased study. Am. J. Gastroenterol. 2012;107(1):89–95. DOI: 10.1038/ajg.2011.398

Novack L., Kogan S., Gimpelevich L., Howell M., Borer A., Kelly C.P., Leffl er D.A., Novack V. Acid suppression therapy does not predispose to Clostridium diffi cile infection: the case of the potential bias. PLoS One. 2014;9(10):e110790. DOI: 10.1371/journal.pone.0110790

Burke K.E., Lamont J.T. Clostridium diffi cile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. DOI: 10.5009/gnl.2014.8.1.1

Kochan T.J., Somers M.J., Kaiser A.M., Shoshiev M.S., Hagan A.K., Hastie J.L., Giordano N.P., Smith A.D., Schubert A.M., Carlson P.E. Jr., Hanna P.C. Intestinal calcium and bile salts facilitate germination of Clostridium diffi cile spores. PLoS Pathog. 2017;13(7):e1006443. DOI: 10.1371/journal.ppat.1006443

Austin M., Mellow M., Tierney W.M. Fecal microbiota transplantation in the treatment of Clostridium diffi cile infections. Am. J. Med. 2014;127(6):479–83. DOI: 10.1016/j.amjmed.2014.02.017

Antharam V.C., Li E.C., Ishmael A., Sharma A., Mai V., Rand K.H., Wang G.P. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium diffi cile infection and nosocomial diarrhea. J. Clin. Microbiol. 2013;51(9):2884–92. DOI: 10.1128/JCM.00845-13

Vincent C., Stephens D.A., Loo V.G., Edens T.J., Behr M.A., Dewar K., Manges A.R. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium diffi cile infection. Microbiome. 2013;1(1):18. DOI: 10.1186/2049-2618-1-18

Gu S., Chen Y., Zhang X., Lu H., Lv T., Shen P., Lv L., Zheng B., Jiang X., Li L. Identifi cation of key taxa that favor intestinal colonization of Clostridium diffi cile in an adult Chinese population. Microbes Infect. 2016;18(1):30–8. DOI: 10.1016/j.micinf.2015.09.008

Zhang L., Dong D., Jiang C., Li Z., Wang X., Peng Y. Insight into alteration of gut microbiota in Clostridium diffi cile infection and asymptomatic C. diffi cile colonization. Anaerobe. 2015;34:1–7. DOI: 10.1016/j.anaerobe.2015.03.008

Francis M.B., Allen C.A., Shrestha R., Sorg J.A. Bile acid recognition by the Clostridium diffi cile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 2013;9(5):e1003356. DOI: 10.1371/journal.ppat.1003356

Buffi e C.G., Bucci V., Stein R.R., McKenney P.T., Ling L., Gobourne A., No D., Liu H., Kinnebrew M., Viale A., Littmann E., van den Brink M.R., Jenq R.R., Taur Y., Sander C., Cross J.R., Toussaint N.C., Xavier J.B., Pamer E.G. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium diffi cile. Nature. 2015;517(7533):205–8. DOI: 10.1038/nature13828

Androga G.O., Hart J., Foster N.F., Charles A., Forbes D., Riley T.V. Infection with Toxin A-Negative, Toxin B-Negative, Binary ToxinPositive Clostridium diffi cile in a Young Patient with Ulcerative Colitis. J. Clin. Microbiol. 2015;53(11):3702–4. DOI: 10.1128/JCM.01810-15

Brito G.A., Sullivan G.W., Ciesla W.P. Jr., Carper H.T., Mandell G.L., Guerrant R.L. Clostridium diffi cile toxin A alters in vitro-adherent neutrophil morphology and function. J. Infect. Dis. 2002;185(9):1297–306. DOI: 10.1086/340236

Péchiné S., Collignon A. Immune responses induced by Clostridium diffi cile. Anaerobe. 2016;41:68–78. DOI: 10.1016/j.anaerobe.2016.04.014

Hughes M., Qazi T., Berg A., Weinberg J., Chen X., Kelly C.P., Farraye F.A. Host immune response to clostridium diffi cile infection in infl ammatory bowel disease patients. Infl amm. Bowel Dis. 2016;22(4):853–61. DOI: 10.1097/MIB.0000000000000696

Li Y., Qian J., Queener E., Shen B. Risk factors and outcome of PCR-detected Clostridium diffi cile infection in ileal pouch patients. Infl amm. Bowel Dis. 2013;19(2):397–403. DOI: 10.1097/MIB.0b013e318280fcb9

D’Aoust J., Battat R., Bessissow T. Management of infl ammatory bowel disease with Clostridium diffi cile infection. World J. Gastroenterol. 2017;23(27):4986–5003. DOI: 10.3748/wjg.v23.i27.4986

Nitzan O., Elias M., Chazan B., Raz R., Saliba W. Clostridium diffi cile and infl ammatory bowel disease: role in pathogenesis and implications in treatment. World J. Gastroenterol. 2013;19(43):7577– 85. DOI: 10.3748/wjg.v19.i43.7577

Rao K., Higgins P.D. Epidemiology, diagnosis, and management of clostridium diffi cile infection in patients with infl ammatory bowel disease. Infl amm. Bowel Dis. 2016;22(7):1744–54. DOI: 10.1097/ MIB.0000000000000793

Ross C.L., Spinler J.K., Savidge T.C. Structural and functional changes within the gut microbiota and susceptibility to Clostridium diffi cile infection. Anaerobe. 2016;41:37–43. DOI: 10.1016/j.anaerobe.2016.05.006

Freeman H.J. Recent developments on the role of Clostridium diffi cile in infl ammatory bowel disease. World J. Gastroenterol. 2008;14(18):2794–6. DOI: 10.3748/wjg.14.2794

Trifan A., Stanciu C., Stoica O., Girleanu I., Cojocariu C. Impact of Clostridium diffi cile infection on infl ammatory bowel disease outcome: a review. World J. Gastroenterol. 2014;20(33):11736–42. DOI: 10.3748/wjg.v20.i33.11736

Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., McFarland L.V., Mellow M., Zuckerbraun B.S. Guidelines for diagnosis, treatment, and prevention of Clostridium diffi cile infections. Am. J. Gastroenterol. 2013;108(4):478–98; quiz 499. DOI: 10.1038/ajg.2013.4

Issa M., Vijayapal A., Graham M.B., Beaulieu D.B., Otterson M.F., Lundeen S., Skaros S., Weber L.R., Komorowski R.A., Knox J.F., Emmons J., Bajaj J.S., Binion D.G. Impact of Clostridium diffi - cile on infl ammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007;5(3):345–51. DOI: 10.1016/j.cgh.2006.12.028

Meyer A.M., Ramzan N.N., Loftus E.V. Jr., Heigh R.I., Leighton J.A. The diagnostic yield of stool pathogen studies during relapses of infl ammatory bowel disease. J. Clin. Gastroenterol. 2004;38(9):772–5. DOI: 10.1097/01.mcg.0000139057.05297.d6

Clayton E.M., Rea M.C., Shanahan F., Quigley E.M., Kiely B., Hill C., Ross R.P. The vexed relationship between Clostridium diffi - cile and infl ammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am. J. Gastroenterol. 2009;104(5):1162–9. DOI: 10.1038/ajg.2009.4

Nguyen G.C., Kaplan G.G., Harris M.L., Brant S.R. A national survey of the prevalence and impact of Clostridium diffi cile infection among hospitalized infl ammatory bowel disease patients. Am. J. Gastroenterol. 2008;103(6):1443–50. DOI: 10.1111/j.1572-0241.2007.01780.x

Gianotti R.J., Moss A.C. The Use and Effi cacy of Fecal Microbiota Transplantation for Refractory Clostridium diffi cile in Patients with Infl ammatory Bowel Disease. Infl amm Bowel Dis. 2016;22(11):2704– 2710. DOI: 10.1097/MIB.0000000000000950

Jabbar U., Leischner J., Kasper D., Gerber R., Sambol S.P., Parada .P., Johnson S., Gerding D.N. Eff ectiveness of alcohol-based hand rubs for removal of Clostridium diffi cile spores from hands. Infect. Control Hosp. Epidemiol. 2010;31(6):565–70. DOI: 10.1086/652772

Cornely O.A., Miller M.A., Louie T.J., Crook D.W., Gorbach S.L. Treatment of fi rst recurrence of Clostridium diffi cile infection: fi daxomicin versus vancomycin. Clin. Infect. Dis. 2012;55(2):S154– 61. DOI: 10.1093/cid/cis462

Bien J., Palagani V., Bozko P. The intestinal microbiota dysbiosis and Clostridium diffi cile infection: is there a relationship with infl ammatory bowel disease? Therap. Adv. Gastroenterol. 2013;6(1):53– 68. DOI: 10.1177/1756283X12454590

Navaneethan U., Venkatesh P.G., Shen B. Clostridium diffi cile infection and infl ammatory bowel disease: understanding the evolving relationship. World J. Gastroenterol. 2010;16(39):4892– 904. DOI: 10.3748/wjg.v16.i39.4892

Hughes M., Qazi T., Berg A., Weinberg J., Chen X., Kelly C.P., Farraye F.A. Host Immune Response to Clostridium diffi cile Infection in Infl ammatory Bowel Disease Patients. Infl amm. Bowel Dis. 2016;22(4):853–61. DOI: 10.1097/MIB.0000000000000696

D’Aoust J., Battat R., Bessissow T. Management of infl ammatory bowel disease with Clostridium diffi cile infection. World J. Gastroenterol. 2017;23(27):4986–5003. DOI: 10.3748/wjg.v23.i27.4986

McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffi n S.E., Dubberke E.R., Garey K.W., Gould C.V., Kelly C., Loo V., Shaklee Sammons J., Sandora T.J., Wilcox M.H. Clini cal Practice Guidelines for Clostridium diffi cile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018;66(7):e1–e48. DOI: 10.1093/cid/cix1085

McFarland L.V. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78. DOI: 10.2217/17460913.3.5.563

Jose S., Madan R. Neutrophil-mediated infl ammation in the pathogenesis of Clostridium diffi cile infections. Anaerobe. 2016;41:85– 90. DOI: 10.1016/j.anaerobe.2016.04.001

Czepiel J., Dróżdż M., Pituch H., Kuijper E.J., Perucki W., Mielimonka A., Goldman S., Wultańska D., Garlicki A., Biesiada G. Clostridium diffi cile infection: review. Eur. J. Clin. Microbiol. Infect. Dis. 2019;38(7):1211–1221. DOI: 10.1007/s10096-019-03539-6

Wilcox M.H., Fawley W.N., Wigglesworth N., Parnell P., Verity P., Freeman J. Comparison of the eff ect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium diffi cile infection. J. Hosp. Infect. 2003;54(2):109–14. DOI: 10.1016/s0195-6701(02)00400-0

Bartlett J.G. Detection of Clostridium diffi cile infection. Infect. Control Hosp. Epidemiol. 2010;31(1):S35–7. DOI: 10.1086/655999

Simor A.E. Diagnosis, management, and prevention of Clostridium diffi cile infection in long-term care facilities: a review. J. Am. Geriatr. Soc. 2010;58(8):1556–64. DOI: 10.1111/j.1532-5415.2010.02958.x

Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные пред ставления об инфекции Clostridium diffi cile. Клиническая микробиология и антимикробная химиотерапия. 2002;3(4):200– 232.

Lobzin Yu.V., Zakharenko S.M., Ivanov G.A. Modern concepts of Clostridium diffi cile infection. Clinical microbiology and antimicrobial chemotherapy. 2002;3(4):200–232. (In Russian). DOI: 10.22328/2413-5747-2017-3-1-14-24

Ивашкин В.Т., Ющук Н.Д, Маев И.В., Лапина Т.Л., Полуэктова Е.А., Шифрин О.С., Тертычный А.С., Трухманов А.С., Шептулин А.А., Баранская Е.К., Ляшенко О.С., Ивашкин К.В. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium diffi cile-ассоциированной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2016;26(5).

Ivashkin V.T., Yushchuk N.D., Maev I.V., Lapina T.L., Poluektova E.A., Shifrin O.S., Tertychny A.S., Trukhmanov A.S., Sheptulin A.A., Baranskaya E.K., Lya shenko O.S., Ivashkin K.V. Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of Clostridium diffi cile-associated disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2016;26(5). (In Russian). DOI: 10.22416/1382-4376-2016-26-5-56-65

Crobach M.J., Planche T., Eckert C., Barbut F., Terveer E.M., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium diffi cile infection. Clin. Microbiol. Infect. 2016;22(4):63–81. DOI: 10.1016/j.cmi.2016.03.010

Ananthakrishnan A.N., Binion D.G. Impact of Clostridium diffi cile on infl ammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2010;4(5):589–600. DOI: 10.1586/egh.10.55

Farooq P.D., Urrunaga N.H., Tang D.M, von Rosenvinge E.C. Pseudomembranous colitis. Dis. Mon. 2015;61(5):181–206. DOI: 10.1016/j.disamonth.2015.01.006

Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium diffi - cile associated diseases. Indian J. Med. Res. 2010;131:487–99.

Bitton A., Buie D., Enns R., Feagan B.G., Jones J.L., Marshall J.K., Whittaker S., Griffi ths A.M., Panaccione R. Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am. J. Gastroenterol. 2012;107(2):179– 94; author reply 195. DOI: 10.1038/ajg.2011.386

McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium diffi cile disease. Am. J. Gastroenterol. 2002;97(7):1769–75. DOI: 10.1111/j.1572-0241.2002.05839.x

Horton H.A., Dezfoli S., Berel D., Hirsch J., Ippoliti A., McGovern D., Kaur M., Shih D., Dubinsky M., Targan S.R., Fleshner P., Vasiliauskas E.A., Grein J., Murthy R., Melmed G.Y. Antibiotics for treatment of clostridium diffi cile infection in hospitalized patients with infl ammatory bowel disease. Antimicrob. Agents Chemother. 2014;58(9):5054–9. DOI: 10.1128/AAC.02606-13

Beniwal-Patel P., Stein D.J., Munoz-Price L.S. The Juncture Between Clostridioides diffi cile Infection and Infl ammatory Bowel Diseases. Clin. Infect. Dis. 2019;69(2):366–372. DOI: 10.1093/cid/ciz061

Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., Bourgault A.M., Nguyen T., Frenette C., Kelly M., Vibien A., Brassard P., Fenn S., Dewar K., Hudson T.J., Horn R., René P., Monczak Y., Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium diffi cile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005;353(23):2442–9. DOI: 10.1056/NEJMoa051639

[Electronic resource]. URL: https://www.sciencephoto.com/media/11348/view

Chung H.S., Park J.S., Shin B.M. Laboratory Diagnostic Methods for Clostridioides diffi cile Infection: the First Systematic Review and Meta-analysis in Korea. Ann. Lab. Med. 2021;41(2):171–180. DOI:10.3343/alm.2021.41.2.171

Bartlett J.G. Bezlotoxumab — A New Agent for Clostridium diffi cile Infection. N. Engl. J. Med. 2017;376(4):381–382. DOI: 10.1056/NEJMe1614726

Wilcox M.H., Gerding D.N., Poxton I.R., Kelly C., Nathan R., Birch T., Cornely O.A., Rahav G., Bouza E., Lee C., Jenkin G., Jensen W., Kim Y.S., Yoshida J., Gabryelski L., Pedley A., Eves K., Tipping R., Guris D., Kartsonis N., Dorr M.B. MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent Clostridium diffi cile Infection. N. Engl. J. Med. 2017;376(4):305– 317. DOI: 10.1056/NEJMoa1602615

Ooijevaar R.E., van Beurden Y.H., Terveer E.M., Goorhuis A., Bauer M.P., Keller J.J., Mulder C.J.J., Kuijper E.J. Update of treatment algorithms for Clostridium diffi cile infection. Clin. Microbiol. Infect. 2018;24(5):452–462. DOI: 10.1016/j.cmi.2017.12.022

Peng Z., Ling L., Stratton C.W., Li C., Polage C.R., Wu B., Tang Y.W. Advances in the diagnosis and treatment of Clostridium diffi cile infections. Emerg. Microbes Infect. 2018;7(1):15. DOI: 10.1038/s41426-017-0019-4

Kassam Z., Lee C.H., Yuan Y., Hunt R.H. Fecal microbiota transplantation for Clostridium diffi cile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 2013;108(4):500–8. DOI: 10.1038/ajg.2013.59

Liubakka A., Vaughn B.P. Clostridium diffi cile Infection and Fecal Microbiota Transplant. AACN Adv. Crit. Care. 2016;27(3):324–337. DOI: 10.4037/aacnacc2016703

Sartelli M., Di Bella S., McFarland L.V., Khanna S., FuruyaKanamori L., Abuzeid N., Abu-Zidan F.M., Ansaloni L., Augustin G., Bala M., Ben-Ishay O., Biffl W.L., Brecher S.M., CamachoOrtiz A., Caínzos M.A., Chan S., Cherry-Bukowiec J.R., Clanton J., Coccolini F., Cocuz M.E., Coimbra R., Cortese F., Cui Y., Czepiel J., Demetrashvili Z., Di Carlo I., Di Saverio S., Dumitru I.M., Eckmann C., Eiland E.H., Forrester J.D., Fraga G.P., Frossard J.L., Fry D.E., Galeiras R., Ghnnam W., Gomes C.A., Griffi ths E.A., Guirao X., Ahmed M.H., Herzog T., Kim J.I., Iqbal T., Isik A., Itani K.M.F., Labricciosa F.M., Lee Y.Y., Juang P., Karamarkovic A., Kim P.K., Kluger Y., Leppaniemi A., Lohsiriwat V., Machain G.M., Marwah S., Mazuski J.E., Metan G., Moore E.E., Moore F.A., Ordoñez C.A., Pagani L., Petrosillo N., Portela F., Rasa K., Rems M., Sakakushev B.E., Segovia-Lohse H., Sganga G., Shelat V.G., Spigaglia P., Tattevin P., Tranà C., Urbánek L., Ulrych J., Viale P., Baiocchi G.L., Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) diffi cile infection in surgical patients. World J. Emerg. Surg. 2019;14:8. DOI: 10.1186/s13017-019-0228-3

Khanna S., Shin A., Kelly C.P. Management of Clostridium diffi cile Infection in Infl ammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin. Gastroenterol. Hepatol. 2017;15(2):166–174. DOI: 10.1016/j.cgh.2016.10.024

The authors declare that there are no conflicts of interest present.